Transferencia génica mediante virus adeno-asociados en un modelo de daño articular en rodilla de rata / Gene transfer mediated by adeno-associated virus vector in a rat knee model of articular damage

El cartílago articular es el tejido encargado de disminuirla fricción entre las superficies articulares durante el movimiento.Su limitada capacidad de regeneración hace quelas lesiones osteocondrales posean un mal pronóstico ypuedan acabar generando una artrosis en la articulación.La terapia génica para este tipo de patologías resulta muyprometedora, puesto que actualmente, no hay ningún procedimientocapaz de restablecer el tejido dañado. En nuestroestudio hemos puesto a punto un modelo de transferenciagénica a los tejidos de la articulación de la rodillade rata, inyectando intraarticularmente vectores derivadosde virus adeno-asociados, capaces de inducir la expresiónde luciferasa. Los resultados muestran cómo la inducciónde la expresión resulta significativa a partir de los dos mesesde evolución en todos los tejidos articulares (cartílagoarticular, menisco, membrana sinovial y hueso subcondral).La presencia de daño, tanto de tipo mecánico comoautoinmune (artritis inducida por colágeno) no modifica laexpresión de proteína por parte del vector

Articular cartilage is a tissue that decreases friction onarticular surfaces during movement. Its limited regenerativecapacity makes osteocondral lessions to extend andgenerate osteoarthritis in the joint. Gene therapy is apromising alternative to these patologies, since there areno proceedings actually, that restablishes damaged tissue.In our study, we have developed a model of gene transferto articular tissues injecting intraarticularly an adeno-associatedderived vector that induces expression of luciferase.Results obtained show a significant induction of proteinexpression two months after injecting vectors, in all articulartissues (articular cartilage, meniscus, synovium andsubcondral bone). The presence of lessions, mechanic orautoimmune (collagen induced arthritis) do not modify theexpression of protein induced by the vector

[Assessment of paclitaxel treatment of non-small-cell lung cancer]. / Evaluación del tratamiento con paclitaxel del cáncer de pulmón no microcítico.

BACKGROUND: Our goal was to assess the effectiveness of paclitaxel therapy in patients with non-small-cell lung cancer (NSCLC) by means of a meta-analysis of published clinical trials. MATERIAL AND METHOD: We carried out a search of controlled and randomized clinical trials which evaluated treatment with paclitaxel in patients with NSCLC from January 1996 to April 2001, regardless of any other associated therapy and without restrictions in the publication language. We also performed a sensitivity analysis and an analysis of sample heterogeneity. RESULTS: Six randomized and controlled studies fulfilled the inclusion criteria. Results from the analysis of effectiveness favoured significantly treatment with paclitaxel (OR 95% total responders: 1.42 [1.16-1.74]; p = 0.07). These results remained unchanged with the sensitivity analysis. Analysis of survival after 1 year of treatment was not significant (OR 95% 0.96 [0.79-1.17]; p = 0.2) CONCLUSIONS: Paclitaxel in patients with NSCLC offers a therapeutic advantage over other chemotherapy regimes with an overall OR of 1.42. However, this therapy does not appear to offer a significant survival advantage after 1 year.